Roclatan

Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Aerie’s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
Three companies on the “Horizon” with glaucoma drugsThe pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
Rocket 2 results may tip the scaleAerie recently reported the results of its second phase III registration trial in the United States named Rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of IOP lowering for Rhopressa compared with timolol.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Fixed-dose combination glaucoma drug provides easy, safe IOP controlOnce-daily dosing of one drop of Roclatan (Aerie Pharmaceuticals, Inc.), containing a fixed-dose combination of latanoprost and a rho kinase inhibitor and norepinephrine transport inhibitor, was clinically and statistically superior to administration of its individual components for controlling IOP in open-angle glaucoma or ocular hypertension.
Directly targeting pathology: A novel approach to treating glaucomaRho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.
Latest glaucoma drugs with new MOA race to NDA submission
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
Fixed dose of ROCK/NET inhibitor, latanoprost meets endpointA fixed-dose combination containing an investigational rho kinase/norepinephrine transporter inhibitor and latanoprost 0.005% achieved its primary endpoint, showing potential as a high-efficacy, IOP-lowering therapy in a phase IIb trial.